Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-25
2005-01-25
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
06846806
ABSTRACT:
This invention relates to a novel class of peptides having the Formula (I):which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.
REFERENCES:
patent: WO 9743310 (1997-11-01), None
patent: WO 9817679 (1998-04-01), None
patent: WO 9822496 (1998-05-01), None
patent: WO 9846630 (1998-10-01), None
patent: WO 9907733 (1999-02-01), None
patent: WO 9907734 (1999-02-01), None
patent: WO 9950230 (1999-10-01), None
patent: WO 0009543 (2000-02-01), None
patent: WO 0009558 (2000-02-01), None
Benet et al. Pharmacokinetics: The dynamics of Drug Absorption, Distribution, adn Elimination. McGraw-Hill (1990): 3-32.*
Manning et al. Stability of Protein Pharmaceuticals. Pharmaceutical Research (1989) 6: 903-918.*
Dimasi et al. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J Virol. 1997 Oct; 71(10):7461-9.*
C. Steinkuhler, et al, “Product Inhibition of the Hepatitis C Virus NS3 Protease,” Biochemistry, 37, pp. 8899-8905, 1998.
P. Ingallinella, et al, “Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products,” Biochemistry, 37, pp. 8906-8914, 1998.
E. Pizzi, et al, “Molecular Model of the Specificity Pocket of the Hepatitis C Virus Protease: Implications for Substrate Recognition,” Proc. Natl. Acad. Sci. USA, 91, pp. 888-892, 1994.
A. Urbani, et al, “Substrate Specificity of the Hepatitis C Virus Serine Protease NS3,” The Journal of Biological Chemistry, 272(14), pp. 9204-9209, 1997.
R. B. Perni, “NS3•4A Protease as a Target for Interfering with Hepatitis C Virus Replication,” Drug News Perspect, 13(2), pp. 69-77, 2000.
Audet Maury A.
Bristol--Myers Squibb Company
Epperson James
Larsen Scott K.
Tate Christopher R.
LandOfFree
Peptide inhibitors of Hepatitis C virus NS3 protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide inhibitors of Hepatitis C virus NS3 protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors of Hepatitis C virus NS3 protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3438871